Nemaura Medical, Inc. operates as a holding company. The company is headquartered in Manhattan, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.
How did NMRD's recent EPS compare to expectations?
The most recent EPS for Nemaura Medical Inc is $, expectations of $-0.11.
How did Nemaura Medical Inc NMRD's revenue perform in the last quarter?
Nemaura Medical Inc revenue for the last quarter is $
What is the revenue estimate for Nemaura Medical Inc?
According to of Wall street analyst, the revenue estimate of Nemaura Medical Inc range from $ to $
What's the earning quality score for Nemaura Medical Inc?
Nemaura Medical Inc has a earning quality score of B+/49.508953. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Nemaura Medical Inc report earnings?
Nemaura Medical Inc next earnings report is expected in 2025-06-22
What are Nemaura Medical Inc's expected earnings?
Nemaura Medical Inc expected earnings is $408.0K, according to wall-street analysts.
Did Nemaura Medical Inc beat earnings expectations?
Nemaura Medical Inc recent earnings of $ expectations.